IR Insights: How Moderna is Helping Advance the Fight Against Cancer
Last week, we announced follow-up data from our phase 2b study evaluating our investigational individualized neoantigen therapy in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, in patients with high-risk melanoma following complete resection.
Members of our team sat down to give an overview of the new data and its implications, and what the future holds for our partnership with Merck as well as Moderna’s oncology franchise. Watch our latest IR Insights video to hear more from Dr. Stephen Hoge, Moderna’s president, and Dr. Kyle Holen, our Head of Development in Oncology and Therapeutics
This post and the accompanying video contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the ability for mRNA-4157/V940 and KEYTRUDA to demonstrate a clinically meaningful improvement in recurrence-free survival and distant metastasis-free survival compared with KEYTRUDA alone, the tolerability and safety profile for mRNA-4157/V940; the ability of an individualized neoantigen therapy to trigger a tailored antitumor response specific to a patient's tumor mutation signature; and plans for studying individualized neoantigen therapy in additional types of cancer. The forward-looking statements in this post are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this post in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this post.